I don't think the manufacturing of A2-73 beyond the amount necessary for clinical trial levels should be speculated upon. It probably makes sense from an economies of scale just to manufacture more than necessary, because the incremental cost of manufacturing more was probably a marginal cost compared to having to go back to the contract manufacturing lab from scratch and synthesize more of the compound.
It also allows for patients who are enrolled to continue on their dosing protocol, if they so choose, beyond the conclusion of the trials.
Was his comment on expiry about using up existing inventory? I would have guessed all that would be considered when trial planning was done. Build/produce enough for trials w/some contingency build. Building additional beyond normal planning will actually expose more inventory to expiration if unused. (we do not know any shelf life issues exist) So anyways, why does a company in clinical trials need to build up product inventory? Good question Biostockclub. My guess is follow more crumbs for the trail.
News 
Market Data 
Discover 
